Where does Immunogen, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Immunogen, Inc. ranks #2,642 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Immunogen, Inc. hold?

Immunogen, Inc. holds 147 US utility patents granted between 2015 and 2025, spanning 15 technology areas.

What is Immunogen, Inc.'s Innovation Score?

Immunogen, Inc. has an Innovation Score of 49.0 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Immunogen, Inc.'s patent grant rate increasing or decreasing?

Immunogen, Inc.'s recent grant velocity is -38% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Immunogen, Inc.'s patents?

Immunogen, Inc.'s patents average 24.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Immunogen, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Immunogen, Inc.

Q: What technology areas does Immunogen, Inc. focus on?

Immunogen, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 119 patents. Grants appear in 15 CPC subclasses total.

USPTO PatentsView assignee record - 147 granted patents across 15 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Immunogen ranks #2,642 of 49,997 tracked US assignees by granted-patent volume, with 147 patents across 15 technology areas.

#2,642
of 49,997 US assignees by volume: Top 15%
by Innovation Score (49.0/100): 24.4
avg claims per patent: -38%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2642 · US Corporation #2,642 · 147 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 147 grants
TOP-DECILE #2,642/49,997
PHOTO-FINISH Cleversafe
CPC-FOCUS A61P · 15 areas
INNOV-PAR 49.0/100
CLAIMS-DENSE 24.4 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -38% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cleversafe, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
GlaxoSmithKline · near

49
Immunogen · this assignee

49
Manicka Institute · near

49
Thales Alenia Space… · near

49
Smartsky Networks · near

49
3D Lighting… · lowest

7

What this shows Immunogen's Innovation Score is 49.0/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Immunogen's grants concentrate

Immunogen, Inc. is a focused PatentsView assignee: 15 CPC subclasses with 81% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (21 grants) versus a trough of 6 in 2024. By volume, Immunogen sits between Cleversafe, Inc. and Lotte Chemical Corporation.

Immunogen's three-year grant acceleration

From 2019–2021 to 2022–2024, Immunogen, Inc. moved from 50 to 26 grants (0.52x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,636. See the growth leaderboard.

Cleversafe

147
Giesecke+Devrient…

147
Hitachi Vantara

147
Hyundai Autron

147
Interface Technol…

147
Intex Marketing

147
James R Glidewell…

147
Lotte Chemical

147
Immunogen ◀

147

What this shows Immunogen holds 147 patents at rank #2,642, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Immunogen

By rank, the assignees closest to #2,642 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Immunogen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Immunogen, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (49 here).

GlaxoSmithKline LLC 49 Thales Alenia Space Italia S.p.A. Con Unico Socio 49 Manicka Institute LLC 49 Smartsky Networks LLC 49

Similar claim depth

Nearest assignees by average claims per patent (24.4 here).

Headwater Partners II LLC 24.4 avg Gigamon Inc. 24.4 avg Cognitive Systems Corp. 24.4 avg Howard Hughes Medical Institute 24.4 avg

Immunogen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Immunogen, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	15	10.2%
2016	21	14.3%
2017	18	12.2%
2018	16	10.9%
2019	20	13.6%
2020	14	9.5%
2021	16	10.9%
2022	11	7.5%
2023	9	6.1%
2024	6	4.1%
2025partial year	1	0.7%

Which technologies does Immunogen, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 119

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 114

C07K - Peptides 109

C07D - Heterocyclic Compounds 78

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 16

C07C - Acyclic OR Carbocyclic Compounds 15

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 12

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 8

Y02A - Technologies FOR Adaptation TO Climate Change 8

H01R - Electrically-conductive CONNECTIONS; Structural Associations OF A Plurality OF Mutually-insulated Electrical Connecting ELEMENTS; Coupling DEVICES; Current Collectors 6

H05K - Printed CIRCUITS; Casings OR Constructional Details OF Electric APPARATUS; Manufacture OF Assemblages OF Electrical Components 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 2

B01D - Separation 1

Top 15 of 15 technology areas

Where it ranks

Overall rank by patents

#2,642

of 49,997 tracked assignees

Innovation Score

49.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Immunogen, Inc.'s patent record in context - here's where to go next.

Immunogen, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 81% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #2,642 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Immunogen, Inc. against Cleversafe, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.